Chas P. Smith & Associates (CPS)’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$377K Sell
13,439
-2,652
-16% -$70.6K 0.02% 120
2025
Q4
$401K Buy
16,091
+2,768
+21% +$69.8K 0.02% 119
2025
Q3
$339K Sell
13,323
-10,295
-44% -$254K 0.03% 98
2025
Q2
$572K Sell
23,618
-20,018
-46% -$467K 0.03% 99
2025
Q1
$1.11M Sell
43,636
-3,220
-7% -$84.3K 0.06% 70
2024
Q4
$1.24M Sell
46,856
-11,663
-20% -$316K 0.07% 64
2024
Q3
$1.69M Sell
58,519
-8,562
-13% -$250K 0.1% 58
2024
Q2
$1.88M Sell
67,081
-11,008
-14% -$303K 0.11% 56
2024
Q1
$2.17M Sell
78,089
-12,252
-14% -$340K 0.13% 51
2023
Q4
$2.6M Sell
90,341
-19,093
-17% -$577K 0.17% 44
2023
Q3
$3.63M Sell
109,434
-24,039
-18% -$850K 0.26% 37
2023
Q2
$4.9M Sell
133,473
-594,461
-82% -$23.1M 0.31% 38
2023
Q1
$29.7M Buy
727,934
+8,108
+1% +$350K 2.02% 27
2022
Q4
$36.9M Buy
719,826
+4,622
+0.6% +$222K 2.62% 20
2022
Q3
$31.3M Buy
715,204
+4,550
+0.6% +$221K 2.66% 18
2022
Q2
$37.3M Buy
710,654
+6,353
+0.9% +$324K 2.69% 17
2022
Q1
$36.5M Sell
704,301
-1,524
-0.2% -$79.1K 2.75% 17
2021
Q4
$41.7M Sell
705,825
-8,073
-1% -$400K 2.84% 14
2021
Q3
$30.7M Buy
713,898
+17,710
+3% +$785K 2.3% 22
2021
Q2
$27.3M Buy
696,188
+16,960
+2% +$660K 2.12% 27
2021
Q1
$24.6M Buy
679,228
+29,359
+5% +$1.04M 2.31% 24
2020
Q4
$23.9M Sell
649,869
-19,421
-3% -$712K 2.4% 25
2020
Q3
$23.3M Sell
669,290
-4,535
-0.7% -$159K 2.62% 23
2020
Q2
$20.9M Sell
673,825
-2,820
-0.4% -$95.8K 2.54% 23
2020
Q1
$21M Buy
676,645
+15,949
+2% +$543K 2.9% 16
2019
Q4
$24.6M Buy
660,696
+2,109
+0.3% +$75.1K 2.67% 20
2019
Q3
$22.5M Sell
658,587
-2,651
-0.4% -$96.4K 2.59% 24
2019
Q2
$27.2M Sell
661,238
-18,674
-3% -$742K 3.2% 8
2019
Q1
$27.4M Sell
679,912
-14,174
-2% -$568K 3.36% 8
2018
Q4
$28.7M Sell
694,086
-21,813
-3% -$906K 3.9% 3
2018
Q3
$29.9M Sell
715,899
-7,031
-1% -$271K 3.65% 5
2018
Q2
$24.9M Buy
722,930
+10,976
+2% +$375K 3.34% 9
2018
Q1
$24M Buy
711,954
+12,116
+2% +$417K 3.33% 9
2017
Q4
$24M Buy
699,838
+17,766
+3% +$606K 3.22% 11
2017
Q3
$23.1M Sell
682,072
-7,708
-1% -$248K 3.3% 10
2017
Q2
$22M Buy
689,780
+6,283
+0.9% +$198K 3.21% 12
2017
Q1
$22.2M Buy
683,497
+62,166
+10% +$1.96M 3.3% 9
2016
Q4
$19.1M Sell
621,331
-599,514
-49% -$18.3M 3.04% 12
2016
Q3
$39M Buy
1,220,845
+616,223
+102% +$20.6M 3.32% 6
2016
Q2
$20.2M Buy
604,622
+497
+0.1% +$15.9K 3.4% 6
2016
Q1
$17M Sell
604,125
-2,259
-0.4% -$64.5K 2.9% 12
2015
Q4
$18.6M Buy
606,384
+544
+0.1% +$17.1K 3.28% 7
2015
Q3
$18.1M Sell
605,840
-11,215
-2% -$360K 3.48% 7
2015
Q2
$19.6M Buy
617,055
+8,760
+1% +$286K 3.44% 9
2015
Q1
$20.1M Buy
608,295
+4,398
+0.7% +$140K 3.6% 9
2014
Q4
$17.8M Buy
603,897
+16,941
+3% +$486K 3.23% 9
2014
Q3
$16.5M Buy
586,956
+32,641
+6% +$916K 3.27% 8
2014
Q2
$15.6M Sell
554,315
-1,063,039
-66% -$30.3M 3.17% 8
2014
Q1
$49.3M Buy
1,617,354
+32,497
+2% +$969K 3.63% 4
2013
Q4
$46.1M Buy
1,584,857
+1,065,617
+205% +$31M 3.56% 5
2013
Q3
$14.2M Buy
519,240
+14,450
+3% +$393K 3.62% 3
2013
Q2
$13.4M Buy
+504,790
New +$13.9M 3.57% 2

Other funds holding PFE

Chas P. Smith & Associates (CPS)'s PFE Position: Q1 2026 in Review

Chas P. Smith & Associates (CPS) reduced its Pfizer (PFE) stake by 16% in Q1 2026, selling an estimated $70.6K and leaving 13,439 shares worth $377K. The position accounts for 0.02% of the portfolio, ranked #120.

Chas P. Smith & Associates (CPS) first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $49.3M in Q1 2014. 2,935 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Chas P. Smith & Associates (CPS) held 13,439 shares of Pfizer worth $377K as of Q1 2026.
  • Chas P. Smith & Associates (CPS) sold 2,652 Pfizer shares in Q1 2026, an estimated $70.6K.
  • Pfizer made up 0.02% of Chas P. Smith & Associates (CPS)'s portfolio in Q1 2026, its #120 holding.
  • Chas P. Smith & Associates (CPS) first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Chas P. Smith & Associates (CPS)'s Pfizer position peaked at $49.3M in Q1 2014.
  • 2,935 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Chas P. Smith & Associates (CPS)'s 13F filing for Q1 2026, filed 12 May 2026.